Commission Regulation (EU) No 605/2014

law://eu/reg/2014/605@2026-11-13

Contents

THE EUROPEAN COMMISSION,Having regard to the Treaty on the Functioning of the European Union,Having regard to the Act concerning the conditions of accession of the Republic of Croatia and the adjustments to the Treaty on European Union and the Treaty establishing the European Atomic Energy Community^note, and in particular Article 50 thereof,Having regard to Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006^note, and in particular Article 37(5) thereof,Whereas:

(1)Commission Regulation (EU) No 487/2013^note amends some of the language tables for hazard statements included in Annex III to Regulation (EC) No 1272/2008 and some of the language tables for precautionary statements included in Annex IV to that Regulation. With the accession of Croatia to the European Union on 1 July 2013, it is necessary that all hazard and precautionary statements provided for by Regulation (EC) No 1272/2008 as amended by Commission Regulation (EU) No 487/2013 are available in the Croatian language as well. This Regulation introduces the necessary adjustments to the language tables.

(2)Part 3 of Annex VI to Regulation (EC) No 1272/2008 contains two lists of harmonised classification and labelling of hazardous substances. Table 3.1 lists the harmonised classification and labelling of hazardous substances based on the criteria set out in Parts 2 to 5 of Annex I to Regulation (EC) No 1272/2008. Table 3.2 lists the harmonised classification and labelling of hazardous substances based on the criteria set out in Annex VI to Council Directive 67/548/EEC^note.

(3)Proposals for new or updated harmonised classification and labelling of certain substances have been submitted to the European Chemicals Agency (ECHA) pursuant to Article 37 of Regulation (EC) No 1272/2008. Based on the opinions on those proposals issued by the Committee for Risk Assessment of ECHA, as well as on the comments received from the parties concerned, it is appropriate to introduce, remove or update harmonised classification and labelling of certain substances by amending Annex VI to that Regulation.

(4)Compliance with the new harmonised classifications should not be required immediately, as a certain period of time will be necessary to allow suppliers to adapt the labelling and packaging of substances and mixtures to the new classifications and to sell existing stocks. In addition, a certain period of time will be necessary to allow suppliers to comply with the registration obligations resulting from the new harmonised classifications for substances classified as carcinogenic, mutagenic or toxic to reproduction, categories 1A and 1B (Table 3.1) and categories 1 and 2 (Table 3.2), or as very toxic to aquatic organisms which may cause long term effects in the aquatic environment, in particular with those set out in Article 23 of Regulation (EC) No 1907/2006 of the European Parliament and of the Council^note.

(5)In line with the transitional provisions of Regulation (EC) No 1272/2008 which allow the application of the new provisions at an earlier stage on a voluntary basis, suppliers should have the possibility of applying the new harmonised classifications and of adapting the labelling and packaging accordingly on a voluntary basis before the deadline for compliance.

(6)The measures provided for in this Regulation are in accordance with the opinion of the Committee established under Article 133 of Regulation (EC) No 1907/2006,

HAS ADOPTED THIS REGULATION:

Article 1 #

Regulation (EC) No 1272/2008 is amended as follows:

(1)Annex III is amended in accordance with Annex I to this Regulation;

(2)Annex IV is amended in accordance with Annex II to this Regulation;

(3)Annex VI is amended in accordance with Annex III to this Regulation.

Article 2 #

1.By way of derogation from Article 3(2), substances and mixtures may, before 1 December 2014 and 1 June 2015 respectively, be classified, labelled and packaged in accordance with this Regulation.

2.By way of derogation from Article 3(2), substances classified, labelled and packaged in accordance with Regulation (EC) No 1272/2008 and placed on the market before 1 December 2014, shall not be required to be relabelled and repackaged in accordance with this Regulation until 1 December 2016.

3.By way of derogation from Article 3(2), mixtures classified, labelled and packaged in accordance with Directive 1999/45/EC of the European Parliament and of the Council^note or Regulation (EC) No 1272/2008 and placed on the market before 1 June 2015, shall not be required to be relabelled and repackaged in accordance with this Regulation until 1 June 2017.

4.By way of derogation from Article 3(3), the harmonised classifications set out in Annex III to this Regulation may be applied before the date referred to in Article 3(3).

Article 3 #

1.This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.

2.Article 1(1) and (2) shall apply in respect of substances from 1 December 2014 and in respect of mixtures from 1 June 2015.

3.Article 1(3) shall apply from 1 January 2016.

Annex I

(1)in code H229, the following is inserted after the entry corresponding to GA:| HR | Spremnik pod tlakom: može se rasprsnuti ako se grije.

(2)in code H230, the following is inserted after the entry corresponding to GA:| HR | Može eksplozivno reagirati i bez prisustva zraka.

(3)in code H231, the following is inserted after the entry corresponding to GA:| HR | Može eksplozivno reagirati i bez prisustva zraka na povišenom tlaku i/ili temperaturi.

In Part 1 of Annex III, Table 1.1 is amended as follows:

Annex II

(1)Table 1.2 is amended as follows:

(a)in code P210, the following is inserted after the entry corresponding to GA:| HR | Čuvati odvojeno od topline, vrućih površina, iskri, otvorenih plamena i ostalih izvora paljenja. Ne pušiti.

(b)in code P223: The following is inserted after the entry corresponding to GA:| HR | Spriječiti dodir s vodom.

(c)in code P244, the following is inserted after the entry corresponding to GA:| HR | Spriječiti dodir ventila i spojnica s uljem i masti.

(d)in code P251, the following is inserted after the entry corresponding to GA:| HR | Ne bušiti, niti paliti čak niti nakon uporabe.

(e)in code P284, the following is inserted after the entry corresponding to GA:| HR | [U slučaju nedovoljne ventilacije] nositi sredstva za zaštitu dišnog sustava.

(2)Table 1.3 is amended as follows:

(a)in code P310, the following is inserted after the entry corresponding to GA:| HR | Odmah nazvati CENTAR ZA KONTROLU OTROVANJA/liječnika/…

(b)in code P 311, the following is inserted after the entry corresponding to GA:| HR | Nazvati CENTAR ZA KONTROLU OTROVANJA/liječnika/…

(c)in code P312: The following is inserted after the entry corresponding to GA:| HR | U slučaju zdravstvenih tegoba nazvati CENTAR ZA KONTROLU OTROVANJA/liječnika/…

(d)in code P340, the following is inserted after the entry corresponding to GA:| HR | Premjestiti osobu na svježi zrak i postaviti ju u položaj koji olakšava disanje.

(e)in code P352, the following is inserted after the entry corresponding to GA:| HR | Oprati velikom količinom vode/…

(f)in code P361, the following is inserted after the entry corresponding to GA:| HR | Odmah skinuti svu zagađenu odjeću.

(g)in code P362, the following is inserted after the entry corresponding to GA:| HR | Skinuti zagađenu odjeću.

(h)in code P364, the following is inserted after the entry corresponding to GA:| HR | I oprati je prije ponovne uporabe.

(i)in code P378, the following is inserted after the entry GA:| HR | Za gašenje rabiti …

(j)in combined codes P301 + P310, the following is inserted after the entry corresponding to GA:| HR | AKO SE PROGUTA: odmah nazvati CENTAR ZA KONTROLU OTROVANJA/liječnika/…

(k)in combined codes P301 + P312, the following is inserted after the entry corresponding to GA:| HR | AKO SE PROGUTA: u slučaju zdravstvenih tegoba nazvati CENTAR ZA KONTROLU OTROVANJA/liječnika/…

(l)in combined codes P302 + P352, the following is inserted after the entry corresponding to GA:| HR | U SLUČAJU DODIRA S KOŽOM: oprati velikom količinom vode/…

(m)in combined codes P303 + P361+P353, the following is inserted after the entry corresponding to GA:| HR | U SLUČAJU DODIRA S KOŽOM (ili kosom): odmah skinuti svu zagađenu odjeću. Isprati kožu vodom/tuširanjem.

(n)in combined codes P304 + P340, the following is inserted after the entry corresponding to GA:| HR | AKO SE UDIŠE: premjestiti osobu na svježi zrak i postaviti ju u položaj koji olakšava disanje.

(o)in combined codes P308 + P311, the following is inserted after the entry corresponding to GA:| HR | U SLUČAJU izloženosti ili sumnje na izloženost: nazvati CENTAR ZA KONTROLU OTROVANJA/liječnika/…

(p)in combined codes P342 + P311, the following is inserted after the entry corresponding to GA:| HR | Pri otežanom disanju: nazvati CENTAR ZA KONTROLU OTROVANJA/liječnika/…

(q)in combined codes P361 + P364, the following is inserted after the entry corresponding to GA:| HR | Odmah skinuti svu zagađenu odjeću i oprati je prije ponovne uporabe.

(r)in combined codes P362 + P364, the following is inserted after the entry corresponding to GA:| HR | Skinuti zagađenu odjeću i oprati je prije ponovne uporabe.

(s)in combined codes P370 + P378, the following is inserted after the entry corresponding to GA:| HR | U slučaju požara: za gašenje rabiti …

Part 2 to Annex IV is amended as follows:

III

(1)Table 3.1 is amended as follows:

(a)the entry corresponding to index number 015-188-00-X is deleted;

(b)the entries corresponding to index numbers 006-086-00-6, 015-154-00-4, 015-192-00-1, 601-023-00-4, 601-026-00-0, 603-061-00-7, 605-001-00-5, 605-008-00-3 and 616-035-00-5 are replaced by the following corresponding entries:006-086-00-6 | fenoxycarb (ISO); ethyl [2-(4-phenoxyphenoxy)ethyl]carbamate | 276-696-7 | 72490-01-8 | Carc. 2Aquatic Acute 1Aquatic Chronic 1 | H351H400H410 | GHS08GHS09Wng | H351H410 | | M = 1M = 10000 |015-154-00-4 | ethephon; 2-chloroethylphosphonic acid | 240-718-3 | 16672-87-0 | Acute Tox. 3Acute Tox. 4Acute Tox. 4Skin Corr. 1CAquatic Chronic 2 | H311H332H302H314H411 | GHS06GHS05GHS09Dgr | H311H332H302H314H411 | EUH071 | |015-192-00-1 | tetrakis(2,6-dimethylphenyl)-m-phenylene biphosphate | 432-770-2 | 139189-30-3 | Skin Sens. 1 | H317 | GHS07Wng | H317 | | |601-023-00-4 | ethylbenzene | 202-849-4 | 100-41-4 | Flam. Liq. 2Acute Tox. 4*STOT RE 2Asp. Tox. 1 | H225H332H373 (hearing organs)H304 | GHS02GHS07GHS08Dgr | H225H332H373 (hearing organs)H304 | | |601-026-00-0 | styrene | 202-851-5 | 100-42-5 | Flam. Liq. 3Repr. 2Acute Tox. 4*STOT RE 1Skin Irrit. 2Eye Irrit. 2 | H226H361dH332H372 (hearing organs)H315H319 | GHS02GHS08GHS07Dgr | H226H361dH332H372 (hearing organs)H315H319 | | * | D603-061-00-7 | tetrahydro-2-furylmethanol;tetrahydrofurfuryl alcohol | 202-625-6 | 97-99-4 | Repr. 1BEye Irrit. 2 | H360DfH319 | GHS08GHS07Dgr | H360DfH319 | | |605-001-00-5 | formaldehyde …% | 200-001-8 | 50-00-0 | Carc. 1BMuta. 2Acute Tox. 3*Acute Tox. 3*Acute Tox. 3*Skin Corr. 1BSkin Sens. 1 | H350H341H301H311H331H314H317 | GHS08GHS06GHS05Dgr | H350H341H301H311H331H314H317 | | *Skin Corr. 1B; H314: C ≥ 25 %Skin Irrit. 2; H315: 5 % ≤ C < 25 %Eye Irrit. 2; H319: 5 % ≤ C < 25 %STOT SE 3; H335: C ≥ 5 %Skin Sens. 1; H317: C ≥ 0,2 % | B, D605-008-00-3 | acrolein;prop-2-enal;acrylaldehyde | 203-453-4 | 107-02-8 | Flam. Liq. 2Acute Tox. 1Acute Tox. 2Acute Tox. 3Skin Corr. 1BAquatic Acute 1Aquatic Chronic 1 | H225H330H300H311H314H400H410 | GHS02GHS06GHS05GHS09Dgr | H225H330H300H311H314H410 | EUH071 | Skin Corr. 1B;H314: C ≥ 0,1 %M = 100M = 1 | D616-035-00-5 | cymoxanil (ISO);2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide | 261-043-0 | 57966-95-7 | Repr. 2Acute Tox. 4STOT RE 2Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 | H361fdH302H373 (blood, thymus)H317H400H410 | GHS08GHS07GHS09Wng | H361fdH302H373 (blood, thymus)H317H410 | | M = 1M = 1 |

(c)the following entries are inserted in accordance with the order of the entries set out in Table 3.1:050-028-00-2 | 2-ethylhexyl 10-ethyl-4,4-dimethyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate | 260-829-0 | 57583-35-4 | Repr. 2Acute Tox. 4STOT RE 1Skin Sens. 1A | H361dH302H372 (nervous system, immune system)H317 | GHS08GHS07Dgr | H361dH302H372 (nervous system, immune system)H317 | | |050-029-00-8 | dimethyltin dichloride | 212-039-2 | 753-73-1 | Repr. 2Acute Tox. 2Acute Tox. 3Acute Tox. 3STOT RE 1Skin Corr. 1B | H361dH330H301H311H372 (nervous system, immune system)H314 | GHS08GHS06GHS05Dgr | H361dH330H301H311H372 (nervous system, immune system)H314 | EUH071 | |601-088-00-9 | 4-vinylcyclohexene | 202-848-9 | 100-40-3 | Carc. 2 | H351 | GHS08Wng | H351 | | |601-089-00-4 | muscalure; cis-tricos-9-ene | 248-505-7 | 27519-02-4 | Skin Sens. 1B | H317 | GHS07Wng | H317 | | |604-090-00-8 | 4-tert-butylphenol | 202-679-0 | 98-54-4 | Repr. 2Skin Irrit. 2Eye Dam. 1 | H361fH315H318 | GHS08GHS05Dgr | H361fH315H318 | | |604-091-00-3 | etofenprox (ISO); 2-(4-ethoxyphenyl)-2-methylpropyl 3-phenoxybenzyl ether | 407-980-2 | 80844-07-1 | Lact.Aquatic Acute 1Aquatic Chronic 1 | H362H400H410 | GHS09Wng | H362H410 | | M = 100M = 1000 |606-146-00-7 | tralkoxydim (ISO); 2-(N-ethoxypropanimidoyl)-3-hydroxy-5-mesitylcyclohex-2-en-1-one | - | 87820-88-0 | Carc. 2Acute Tox. 4Aquatic Chronic 2 | H351H302H411 | GHS08GHS07GHS09Wng | H351H302H411 | | |606-147-00-2 | cycloxydim (ISO); 2-(N-ethoxybutanimidoyl)-3-hydroxy-5-(tetrahydro-2H-thiopyran-3-yl)cyclohex-2-en-1-one | 405-230-9 | 101205-02-1 | Repr. 2 | H361d | GHS08Wng | H361d | | |607-705-00-8 | benzoic acid | 200-618-2 | 65-85-0 | STOT RE 1Skin Irrit. 2Eye Dam. 1 | H372 (lungs) (inhalation)H315H318 | GHS08GHS05Dgr | H372 (lungs) (inhalation)H315H318 | | |607-706-00-3 | methyl 2,5-dichlorobenzoate | 220-815-7 | 2905-69-3 | Acute Tox. 4STOT SE 3Aquatic Chronic 2 | H302H336H411 | GHS07GHS09Wng | H302H336H411 | | |612-287-00-5 | fluazinam (ISO); 3-chloro-N-[3-chloro-2,6-dinitro-4-(trifluoromethyl)phenyl]-5-(trifluoromethyl)pyridin-2-amine | - | 79622-59-6 | Repr. 2Acute Tox. 4Eye Dam. 1Skin Sens. 1AAquatic Acute 1Aquatic Chronic 1 | H361dH332H318H317H400H410 | GHS08GHS07GHS05GHS09Dgr | H361dH332H318H317H410 | | M = 10M = 10 |613-317-00-X | penconazole (ISO); 1-[2-(2,4-dichlorophenyl)pentyl]-1H-1,2,4-triazole | 266-275-6 | 66246-88-6 | Repr. 2Acute Tox. 4Aquatic Acute 1Aquatic Chronic 1 | H361dH302H400H410 | GHS08GHS07GHS09Wng | H361dH302H410 | | M = 1M = 1 |613-318-00-5 | fenpyrazamine (ISO); S-allyl 5-amino-2-isopropyl-4-(2-methylphenyl)-3-oxo-2,3-dihydro-1H-pyrazole-1-carbothioate | - | 473798-59-3 | Aquatic Chronic 2 | H411 | GHS09 | H411 | | |616-212-00-7 | 3-iodo-2-propynyl butylcarbamate; 3-iodoprop-2-yn-1-yl butylcarbamate | 259-627-5 | 55406-53-6 | Acute Tox. 3Acute Tox. 4STOT RE 1Eye Dam. 1Skin Sens. 1Aquatic Acute 1Aquatic Chronic 1 | H331H302H372 (larynx)H318H317H400H410 | GHS06GHS08GHS05GHS09Dgr | H331H302H372 (larynx)H318H317H410 | | M = 10M = 1 |

(2)Table 3.2 is amended as follows:

(a)the entry corresponding to index number 015-188-00-X is deleted;

(b)the entries corresponding to index numbers 006-086-00-6, 015-154-00-4, 015-192-00-1, 601-023-00-4, 601-026-00-0, 603-061-00-7, 605-001-00-5 and 616-035-00-5 are replaced by the following corresponding entries:006-086-00-6 | fenoxycarb (ISO);ethyl [2-(4-phenoxyphenoxy)ethyl]carbamate | 276-696-7 | 72490-01-8 | Carc. Cat. 3; R40N; R50-53 | Xn; NR: 40-50/53S: (2-)22-36/37-60-61 | N; R50-53: C ≥ 25 %N; R51-53: 2,5 % ≤ C < 25 %R52-53: 0,25 % ≤ C < 2,5 % |015-154-00-4 | ethephon; 2-chloroethylphosphonic acid | 240-718-3 | 16672-87-0 | C; R34Xn; R20/21/22N; R51-53 | C; NR: 20/21/22-34-51/53S: (1/2-)26-36/37/39-45-61 | Xi; R37: 5 % ≤ C < 10 % |015-192-00-1 | tetrakis(2,6-dimethylphenyl)-m-phenylene biphosphate | 432-770-2 | 139189-30-3 | R43 | XiR: 43S: (2-)24-37 | |601-023-00-4 | ethylbenzene | 202-849-4 | 100-41-4 | F; R11Xn; R20-48/20-65 | F; XnR: 11-20-48/20-65S: (2-)16-24/25-29-62 | |601-026-00-0 | styrene | 202-851-5 | 100-42-5 | Repr. Cat. 3; R63Xn; R20-48/20Xi; R36/38R10 | XnR: 10-20-36/38-48/20-63S: (2-)23-36/37-46 | Xn; R20: C ≥ 12,5 %Xi; R36/38: C ≥ 12,5 % | D603-061-00-7 | tetrahydro-2-furylmethanol;tetrahydrofurfuryl alcohol | 202-625-6 | 97-99-4 | Repr. Cat. 2; R61Repr. Cat. 3; R62Xi; R36 | TR: 36-61-62S: 45-53 | Xi; R36: C ≥ 10 % |605-001-00-5 | formaldehyde …% | 200-001-8 | 50-00-0 | Carc. Cat. 2; R45Muta. Cat. 3; R68T; R23/24/25C; R34R43 | TR: 23/24/25-34-43-45-68S: 45-53 | T; R23/24/25: C ≥ 25 %Xn; R20/21/22: 5 % ≤ C < 25 %C; R34: C ≥ 25 %Xi; R36/37/38: 5 % ≤ C < 25 %R43: C ≥ 0,2 % | B, D616-035-00-5 | cymoxanil (ISO);2-cyano-N-[(ethylamino)carbonyl]-2-(methoxyimino)acetamide | 261-043-0 | 57966-95-7 | Repr. Cat. 3; R62-63Xn; R22-48/22R43N; R50-53 | Xn; NR: 22-43-48/22-62-63-50/53S: (2-)36/37-46-60-61 | N; R50-53: C ≥ 25 %N; R51-53: 2,5 % ≤ C < 25 %R52-53: 0,25 % ≤ C < 2,5 % |

(c)the following entries are inserted in accordance with the order of the entries set out in Table 3.2:050-028-00-2 | 2-ethylhexyl 10-ethyl-4,4-dimethyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate | 260-829-0 | 57583-35-4 | Repr. Cat. 3; R63T; R48/25Xn; R22R43 | TR: 22-43-48/25-63S: (1/2-)36/37-45 | |050-029-00-8 | dimethyltin dichloride | 212-039-2 | 753-73-1 | Repr. Cat. 3; R63T+; R26T; R24/25-48/25C; R34 | T+R: 24/25-26-34-48/25-63S: (1/2-)26-28-36/37/39-45-63 | |601-088-00-9 | 4-vinylcyclohexene | 202-848-9 | 100-40-3 | Carc. Cat. 3; R40 | XnR: 40S: (2-)36/37 | |601-089-00-4 | muscalure; cis-tricos-9-ene | 248-505-7 | 27519-02-4 | R43 | XiR: 43S: (2-)24-37 | |604-090-00-8 | 4-tert-butylphenol | 202-679-0 | 98-54-4 | Repr. Cat. 3; R62Xi; R38-41 | XnR: 38-41-62S: (2-)26-36/37/39-46 | |604-091-00-3 | etofenprox (ISO); 2-(4-ethoxyphenyl)-2-methylpropyl 3-phenoxybenzyl ether | 407-980-2 | 80844-07-1 | R64N; R50-53 | NR: 50/53-64S: 60-61 | N; R50-53: C ≥ 0,25 %N; R51-53: 0,025 % ≤ C < 0,25 %R52-53: 0,0025 % ≤ C < 0,025 % |606-146-00-7 | tralkoxydim (ISO); 2-(N-ethoxypropanimidoyl)-3-hydroxy-5-mesitylcyclohex-2-en-1-one | – | 87820-88-0 | Carc. Cat. 3; R40Xn; R22N; R51-53 | Xn; NR: 22-40-51/53S: (2-)36/37-60-61 | |606-147-00-2 | cycloxydim (ISO); 2-(N-ethoxybutanimidoyl)-3-hydroxy-5-(tetrahydro-2H-thiopyran-3-yl)cyclohex-2-en-1-one | 405-230-9 | 101205-02-1 | F; R11Repr. Cat. 3; R63 | F; XnR: 11-63S: (2-)16-36/37-46 | |607-705-00-8 | benzoic acid | 200-618-2 | 65-85-0 | T; R48/23Xi; R38-41 | TR: 38-41-48/23S: (1/2-)26-39-45-63 | |607-706-00-3 | methyl 2,5-dichlorobenzoate | 220-815-7 | 2905-69-3 | Xn; R22N; R51-53 | Xn; NR: 22-51/53S: (2-) 46-61 | |612-287-00-5 | fluazinam (ISO); 3-chloro-N-[3-chloro-2,6-dinitro-4-(trifluoromethyl)phenyl]-5-(trifluoromethyl)pyridin-2-amine | - | 79622-59-6 | Repr. Cat. 3; R63Xn; R20Xi; R41R43N; R50-53 | Xn; NR: 20-41-43-50/53-63S: (2-)26-36/37/39-46-60-61 | N; R50-53: C ≥ 2,5 %N; R51-53: 0,25 % ≤ C < 2,5 %R52-53: 0,025 % ≤ C < 0,25 % |613-317-00-X | penconazole (ISO); 1-[2-(2,4-dichlorophenyl)pentyl]-1H-1,2,4-triazole | 266-275-6 | 66246-88-6 | Repr. Cat. 3; R63Xn; R22N; R50-53 | Xn; NR: 22-50/53-63S: (2-) 36/37-46-60-61 | N; R50-53: C ≥ 25 %N; R51-53: 2,5 % ≤ C < 25 %R52-53: 0,25 % ≤ C < 2,5 % |613-318-00-5 | fenpyrazamine (ISO); S-allyl 5-amino-2-isopropyl-4-(2-methylphenyl)-3-oxo-2,3-dihydro-1H-pyrazole-1-carbothioate | - | 473798-59-3 | N; R51-53 | NR: 51/53S: 60-61 | |616-212-00-7 | 3-iodo-2-propynyl butylcarbamate; 3-iodoprop-2-yn-1-yl butylcarbamate | 259-627-5 | 55406-53-6 | T; R23-48/23Xn; R22Xi; R41R43N; R50 | T; NR: 22-23-41-43-48/23-50S: (1/2-)24-26-37/39-45-63 | N; R50: C ≥ 2,5 % |

Part 3 of Annex VI is amended as follows:

Commission Regulation (EU) No 605/2014

Commission Regulation (EU) No 605/2014

Article 1 #

Article 2 #

Article 3 #

Annex I

Annex II

III

Connections

History · 1 version

Key facts

Article 1 #

Article 2 #

Article 3 #

Annex I

Annex II

III